News »
Boult and 4basebio
James Legg, Olga Bohuszewicz and the Boult team have worked with 4basebio to develop an extensive patent portfolio covering the company’s technology in the fields of synthetic DNA and nanoparticle delivery solutions. On 29 July 2024, 4basebio announced a major equity issuance and secondary sale, raising a total of £69.4 million (see here). James assisted the 4basebio management team during investor-led due diligence that led to the transaction.
Dr Heikki Lanckriet (CEO and CSO, 4basebio) said: “IP is a crucial element in the value proposition of 4basebio. James Legg and his team have been instrumental in protecting 4basebio innovations and developing our ever expanding and robust IP estate! It has been a pleasure to work with James, Olga and the wider team and we look forward continuing our exciting partnership as we build the company.”
Dr Amy Walker (COO, 4basebio) said: “James and his team have been critical in the development of our comprehensive IP portfolio, and are an extension of the 4basebio R&D groups with respect to capturing our continued innovation. James, Olga and their wider team have a deep understanding of our core technology platforms and are fantastic to work with. We look forward to continuing our relationship through the company’s next phase of growth’.